How will chemistry companies handling this potential decrease in the volumes of inputs sourced in France?
The reaction really depends on the pharmaceutical industry but I will say that there are several members of Sicos operating in China and that it is normal industrial cooperation to operate in a region where you believe there to be opportunities and a competitive advantage. The advantage of France lies in its research capabilities while the future of the pharmaceutical industry appears reliant on biotechnology capabilities. However, it appears that France is behind its counterparts in the UK, the US and Japan in the development of these technologies. How is Sicos working with biochemical and biotechnology companies to support this sector? Some of Sicos members have agreements with biotech companies for development. Perhaps, in the future we will have to consider changing our association to integrate biotechnologies as they are a precursor to certain chemicals. Defining the border of an association is always difficult because you have to be able to appeal to what all of your members want
